Executive Vice President and Chief Science Officer, professor, DVM, PhD, DSc, 20 years of experience in R&D leadership of the value chain involved in discovery, development and approval of innovative biological medicines within diabetes and other Novo Nordisk focus areas. Since 2000 Executive Vice President and Chief Science Officer responsible for Novo Nordisk's Research and Development organisation - including Regulatory Affairs - with around 5,000 employees spread across the globe: All committed to increasing the future quality of life of patients with diabetes and other chronic diseases through the development of improved, safe and effective engineered protein therapeutics. Innovation drives the R&D portfolio via a unique combination of protein and side chain engineering, drug formulation and delivery in superior injection devices. Served as adjunct Professor of Pharmacology at the Health faculty of University of Copenhagen since 2000; nominated one of “30 stars of Europe” by Business Week in 2003. Several former board memberships; currently on the Board of Directors at University of Copenhagen, Denmark, and Chairman of the Board of Directors at Steno Diabetes Center, Denmark. Former President of the National Academy of Technical Sciences, Denmark.